Trogenix: Valuation, Funding & Investors
Trogenix is a pioneering biotechnology company focused on developing innovative cancer therapies through its proprietary Odysseus® platform. The company specializes in creating precision genetic medicines that target aggressive, treatment-resistant cancers by delivering potent combination payloads that kill cancer cells and stimulate the immune system, while sparing healthy tissue. Trogenix's lead program targets glioblastoma, with additional efforts in colorectal cancer liver metastases and other solid tumors, aiming to transform cancer treatment paradigms with potentially curative "one-and-done" therapies.
Leadership & Board
Latest Estimated Valuation
- Total Amount Raised
- $70M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $70M
- Latest Funding Round
- Series A
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Oct 08, 2025 | Series A | $70.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Eli Lilly and Company | Series A |
| Meltwind | Series A |
| IQ Capital | Series A |
| LongeVC | Series A |
| Calculus Capital | Series A |
| National Brain Tumor Society’s Brain Tumor Investment Fund | Series A |
| Cancer Research Horizons | Series A |
Similar Companies
A snapshot of private companies similar to Trogenix, helping you discover and navigate related company profiles.
Related News and Analysis







